267 related articles for article (PubMed ID: 37457564)
1. Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO).
Piaserico S; Riedl E; Pavlovsky L; Vender RB; Mert C; Tangsirisap N; Haustrup N; Gallo G; Schuster C; Brunner PM
Front Med (Lausanne); 2023; 10():1185523. PubMed ID: 37457564
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting.
Lynde C; Riedl E; Maul JT; Torres T; Pinter A; Fabbrocini G; Daniele F; Brnabic A; Reed C; Wilhelm S; Holzkämper T; Schuster C; Puig L
Adv Ther; 2023 Mar; 40(3):869-886. PubMed ID: 36515803
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO).
Pinter A; Puig L; Schäkel K; Reich A; Zaheri S; Costanzo A; Tsai TF; Smith SD; Lynde C; Brnabic A; Reed C; Hill J; Schuster C; Riedl E; Paul C
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2087-2100. PubMed ID: 35766124
[TBL] [Abstract][Full Text] [Related]
4. Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
Armstrong A; González-Cantero A; Khattri S; Muzy G; Malatestinic WN; Lampropoulou A; Feely M; See SK; Mert C; Blauvelt A
Dermatol Ther (Heidelb); 2024 Apr; 14(4):933-952. PubMed ID: 38521874
[TBL] [Abstract][Full Text] [Related]
5. Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO.
Riedl E; Pinter A; Zaheri S; Costanzo A; Brnabic A; Konicek B; McKenzie R; Lampropoulou A; Rayes ME; Haustrup N; Schuster C
Dermatol Ther (Heidelb); 2024 May; 14(5):1327-1335. PubMed ID: 38649673
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO).
Pinter A; Costanzo A; Khattri S; Smith SD; Carrascosa JM; Tada Y; Riedl E; Reich A; Brnabic A; Haustrup N; Lampropoulou A; Lipkovich I; Kadziola Z; Paul C; Schuster C
Dermatol Ther (Heidelb); 2024 Jun; 14(6):1479-1493. PubMed ID: 38113010
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO).
Travaglini M; Maul JT; Kors C; Zaheri S; Gerwien J; Müller M; Brnabic A; Sabatino S; Schuster C; Tsai TF
Clin Cosmet Investig Dermatol; 2023; 16():2971-2983. PubMed ID: 37881205
[TBL] [Abstract][Full Text] [Related]
8. Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO).
Pinter A; Eyerich K; Costanzo A; Garrelts A; Schuster C; Mert C; Lampropoulou A; Fotiou K; Maul JT; Papp KA
J Dermatolog Treat; 2024 Dec; 35(1):2350227. PubMed ID: 38797734
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of ixekizumab for the treatment of moderate-to-severe plaque psoriasis with involvement of difficult-to-treat areas: A 52-week multicenter retrospective study.
Valenti M; Gargiulo L; Ibba L; Cortese A; Toso F; Orsini D; Lora V; Frascione P; Sena P; Carugno A; Assorgi C; Costanzo A; Narcisi A
J Dermatol; 2024 Jun; 51(6):839-843. PubMed ID: 38292002
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study.
Li Y; Lv C; Dang L; Lin B; Tao J; Zhang C; Zhou X; Ma H; Lu Y; Chen R; Li J; Dou G; Liang Y; Liang Y; Shi Y
Dermatol Ther (Heidelb); 2024 Apr; 14(4):907-918. PubMed ID: 38536616
[TBL] [Abstract][Full Text] [Related]
11. Speed of clinical improvement in the real-world setting from patient-reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks.
Reich A; Pinter A; Maul JT; Vender RB; Torres T; Brnabic A; Haustrup N; Reed C; Schuster C; Riedl E
J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1825-1840. PubMed ID: 37147855
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers.
Orsini D; Gargiulo L; Ibba L; Cascio Ingurgio R; Valenti M; Perugini C; Pacifico A; Maramao FS; Frascione P; Costanzo A; Narcisi A
J Dermatolog Treat; 2023 Dec; 34(1):2220849. PubMed ID: 37288760
[TBL] [Abstract][Full Text] [Related]
13. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
Paller AS; Seyger MMB; Magariños GA; Pinter A; Cather JC; Rodriguez-Capriles C; Zhu D; Somani N; Garrelts A; Papp KA;
JAMA Dermatol; 2022 May; 158(5):533-541. PubMed ID: 35416908
[TBL] [Abstract][Full Text] [Related]
14. Clinical effectiveness of IL-17 and IL-23 inhibitors on difficult-to-treat psoriasis areas (scalp, genital, and palmoplantar sites): a retrospective, observational, single-center, real-life study.
Mastorino L; Burzi L; Frigatti G; Fazio A; Celoria V; Macagno N; Rosset F; Passerini SG; Roccuzzo G; Verrone A; Stroppiana E; Ortoncelli M; Dapavo P; Quaglino P; Ribero S
Expert Opin Biol Ther; 2023; 23(9):929-936. PubMed ID: 37458181
[TBL] [Abstract][Full Text] [Related]
15. Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis.
Menter A; Bhutani T; Ehst B; Elewski B; Jacobson A
Dermatol Ther (Heidelb); 2022 Jun; 12(6):1289-1302. PubMed ID: 35672564
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
Elewski BE; Blauvelt A; Gallo G; Wolf E; McKean-Matthews M; Burge R; Merola JF; Gottlieb AB; Guenther LC
Dermatol Ther (Heidelb); 2022 Apr; 12(4):911-920. PubMed ID: 35279805
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Paller AS; Seyger MMB; Alejandro Magariños G; Bagel J; Pinter A; Cather J; Keller S; Rodriguez Capriles C; Gontijo Lima R; Gallo G; Little CA; Edson-Heredia E; Li L; Xu W; Papp K;
Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070
[TBL] [Abstract][Full Text] [Related]
18. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
19. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).
Seneschal J; Lacour JP; Bewley A; Faurby M; Paul C; Pellacani G; De Simone C; Horne L; Sohrt A; Augustin M; Hammond E; Reich K
J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2566-2573. PubMed ID: 32364296
[TBL] [Abstract][Full Text] [Related]
20. Which Areas Are Still Left in Biologics Responsive Korean Patients with Moderate to Severe Plaque Psoriasis.
Won SH; Shin BS; Bae KN; Son JH; Shin K; Kim HS; Ko HC; Kim MB; Kim BS
Ann Dermatol; 2023 Feb; 35(1):6-10. PubMed ID: 36750453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
